MORRIS PLAINS, N.J., June 25, 2010 (GLOBE NEWSWIRE) -- UCB (Euronext:UCB) and Immunomedics Inc. (Nasdaq:IMMU) today announced that data for new lupus drug candidate, epratuzumab, were presented at the 9th International Congress on Systemic Lupus Erythematosis in Vancouver, Canada. These data showed that, in patients with moderate to severe systemic lupus erythematosus (SLE), epratuzumab provided clinically meaningful1 and statistically significant*1 improvements in disease activity. In the second half of 2010, UCB will initiate two Phase III studies of epratuzumab for the treatment of patients with moderate to severe lupus.
